2007年，引进日本技术与301医院合作开展NK细胞免疫治疗。
In 2007, the company introduced Japanese technology and cooperated with 301 Hospital to carry out NK cell immunotherapy.

2012年，与日本小田医院集团共建康思葆-小田医院免疫研究中心，并与国内知名三甲医院合作开展NK细胞免疫治疗。
In 2012, it established the Immunology Research Center of Cons-Olar Hospital with Oda Hospital Group of Japan, and cooperated with a well-known tertiary hospital in China to carry out NK cell immunotherapy.

2013年，公司申请“蛋白-细胞偶联物、其制备方法和用途”发明专利，2018年获得中、美、日三国授权。
In 2013, the company applied for the invention patent of "protein-cell conjugates, their preparation methods and uses", and in 2018, it was authorized by China, the United States and Japan.

2014年，申请“一种高效扩增自体NK细胞的培养基及培养方法”专利。
In 2014, he applied for a patent for "a medium and culture method for efficient expansion of autologous NK cells".

2015年，在美国佛罗里达大学孵化园设立细胞技术公司，共同申请专利，并获得专利授权。
In 2015, a cell technology company was established in the University of Florida Incubator in the United States, and jointly applied for a patent and obtained patent authorization.

2016年，与北大人民医院合作开展多发性骨髓瘤临床研究。
In 2016, he cooperated with Peking University People's Hospital to carry out clinical research on multiple myeloma.

2019年，与解放军结核病研究所开展蛋白细胞偶联物治疗结核病的动物药效学研究。
In 2019, we carried out animal pharmacodynamic research on protein cell conjugates in the treatment of tuberculosis with the Tuberculosis Research Institute of the People's Liberation Army.

2022年，与首都医科大学附属北京同仁医院合作开展hGP100-NK细胞偶联物注射液对眼部黑色素瘤治疗的（小规模探索性）临床研究。
In 2022, we will cooperate with Beijing Tongren Hospital affiliated to Capital Medical University to carry out a (small-scale exploratory) clinical study of hGP100-NK cell conjugate injection for the treatment of ocular melanoma.

2023年，与不列颠哥伦比亚大学（UBC）和耶鲁大学（YALE）达成细胞技术合作意向。
In 2023, it will reach a cell technology cooperation intention with the University of British Columbia (UBC) and Yale University (YALE).

2024年，润妍泌语产品上市；“自体免疫细胞存储服务”获得中诚信五星级认证；与首都医科大学团队合作“人间充质干细胞来源外泌体治疗急性缺血性脑卒中”项目。
In 2024, RYM products will be launched; "Autologous immune cell storage service" obtained the five-star certification of China Chengxin; Collaborated with the team of Capital Medical University on the project "Human Mesenchymal Stem Cell-derived Exosomes for the Treatment of Acute Ischemic Stroke".